Trinity compound research profile
TB-500
"TB-500" is a confusing name because it doesn't always mean the exact same thing. The FDA officially defines it as a small fragment (a snipped-out piece)...
Research overview
"TB-500" is a confusing name because it doesn't always mean the exact same thing. The FDA officially defines it as a small fragment (a snipped-out piece) of a bigger natural protein called Thymosin beta-4, specifically the 7-amino-acid piece called LKKTETQ (FDA). But many vendors sell products labeled "TB-500" that actually contain the full, much larger 43-amino-acid protein instead. So when someone says "TB-500," they might mean either the tiny fragment or the whole original protein — and this mix-up matters a lot for understanding the research.
Mechanism under study
The full protein, thymosin beta-4, works partly by grabbing onto a building-block molecule inside cells called actin, which is important for cells being able to move around, form new blood vessels, and repair damage — think of it like helping cells "crawl" toward an injury to fix it. Different parts of the full protein handle different jobs: one small region calms inflammation, another helps cells survive, and a third region (which is the actual "TB-500" fragment) is mainly responsible for cell movement, new blood vessel growth, and wound healing (Sosne & Berger 2023).
Human evidence summary
This is where the naming confusion really matters: solid human trial data exists only for the full-length protein (called thymosin beta-4, or the drug-development name RGN-259), not for the small 7-amino-acid fragment most vendors call "TB-500." In an eye-drop trial for a nerve-related corneal disease, 6 out of 10 people using the treatment fully healed at 4 weeks versus just 1 of 8 using placebo, with a further larger trial now underway (Int J Mol Sci 2022; NCT05555589). However, a separate trial testing it for dry eye disease actually missed its main goals, even though some secondary measurements improved (Clin Ophthalmol 2015). Importantly, systemic injectable use — the way most people actually use "TB-500" for tendon, muscle, or ligament injuries — has never been studied in humans at all; that entire use case is completely unstudied and based only on personal reports.
Preclinical evidence summary
In rodent studies, the full-length protein improved outcomes in models of traumatic brain injury as well as heart and skin repair (Front Endocrinol 2021).
Source material
Use the linked publications and records to evaluate study design, population, limitations, and relevance.